Genprex (NASDAQ:GNPX) Posts Earnings Results

Genprex (NASDAQ:GNPX) released its quarterly earnings results on Wednesday. The company reported ($0.64) earnings per share for the quarter, Zacks reports.

Genprex Stock Performance

Genprex stock traded up $0.02 during trading on Wednesday, hitting $0.85. The company’s stock had a trading volume of 178,655 shares, compared to its average volume of 1,019,538. The stock’s fifty day moving average is $1.47 and its 200 day moving average is $2.47. Genprex has a 1-year low of $0.81 and a 1-year high of $55.00. The stock has a market capitalization of $8.87 million, a price-to-earnings ratio of -0.03 and a beta of -0.94.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP increased its stake in Genprex (NASDAQ:GNPX) by 11.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the period. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 as of its most recent SEC filing. 14.05% of the stock is currently owned by institutional investors.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.